S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:PPBT

Purple Biotech Stock Forecast, Price & News

$4.14
+0.04 (+0.98 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.75
Now: $4.14
$4.22
50-Day Range
$3.97
MA: $4.95
$6.99
52-Week Range
$2.20
Now: $4.14
$14.40
Volume426,967 shs
Average Volume1.14 million shs
Market Capitalization$65.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.33
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PPBT
CUSIPN/A
CIKN/A
Phone972 3 933 3121
Employees9
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1 million
Book Value$5.56 per share

Profitability

Miscellaneous

Market Cap$65.10 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

0.63 out of 5 stars

Medical Sector

1316th out of 1,972 stocks

Pharmaceutical Preparations Industry

587th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$4.14
+0.04 (+0.98 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PPBT News and Ratings via Email

Sign-up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Purple Biotech (NASDAQ:PPBT) Frequently Asked Questions

Is Purple Biotech a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Purple Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Purple Biotech stock.
View analyst ratings for Purple Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Purple Biotech?

Wall Street analysts have given Purple Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Purple Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Purple Biotech?

Purple Biotech saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 353,100 shares, an increase of 90.1% from the January 28th total of 185,700 shares. Based on an average daily trading volume, of 839,300 shares, the short-interest ratio is presently 0.4 days.
View Purple Biotech's Short Interest
.

Who are Purple Biotech's key executives?

Purple Biotech's management team includes the following people:
  • Mr. Isaac Israel, CEO & Director (Age 43, Pay $564.48k)
  • Mr. Gil Efron CPA, M.A., Deputy CEO & CFO (Age 55, Pay $356.91k)
  • Mr. Avraham Shlomo Ben-Tzvi, Group Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Simcha Rock CPA, M.B.A., CPA, MBA, Strategic Advisor & Director (Age 71)
  • Dr. Bertrand C. Liang, Chief Medical Officer (Age 58)
  • Dr. Michael Schickler, Head of Clinical Operations (Age 62)

Who are some of Purple Biotech's key competitors?

What is Purple Biotech's stock symbol?

Purple Biotech trades on the NASDAQ under the ticker symbol "PPBT."

Who are Purple Biotech's major shareholders?

Purple Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (2.20%), Renaissance Technologies LLC (0.82%), Virtu Financial LLC (0.15%) and Washington Trust Bank (0.10%).

Which institutional investors are buying Purple Biotech stock?

PPBT stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Renaissance Technologies LLC, Virtu Financial LLC, and Washington Trust Bank.

How do I buy shares of Purple Biotech?

Shares of PPBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Purple Biotech's stock price today?

One share of PPBT stock can currently be purchased for approximately $4.14.

How much money does Purple Biotech make?

Purple Biotech has a market capitalization of $65.10 million and generates $1 million in revenue each year. The company earns $-5,850,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does Purple Biotech have?

Purple Biotech employs 9 workers across the globe.

What is Purple Biotech's official website?

The official website for Purple Biotech is www.kitovpharma.com.

Where are Purple Biotech's headquarters?

Purple Biotech is headquartered at ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101.

How can I contact Purple Biotech?

Purple Biotech's mailing address is ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101. The company can be reached via phone at 972 3 933 3121 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.